Fig. 3.

Radiographic score in severe COVID-19 patients at baseline and one week after standard-of-care (n = 10) and tocilizumab treatment (n = 19). (A) Vascular score, lung parenchymal score and total radiographic score at baseline (gray dots) and after one week after (light blue dots) in severe COVID-19 patients undergoing standard-of-care (SOC) or receiving tocilizumab (TCZ) in addition to SOC. * p < 0.05, ***p < 0.001 calculated with paired two-tailed Student’s t-test; ns not significant. (B) Representative chest radiographs of one severe COVID-19 patient prior (upper panel) and one week after (lower panel) treatment with tocilizumab. The vascular radiographic score improves both in terms of density (arrows) and dimension (asterisk) of hilar vessels.